Search

Bio Roundup: Drug Prices, CRISPR Caveats, Rubius IPO Pop & More

BIO ROUNDUP: DRUG PRICES, CRISPR CAVEATS, RUBIUS IPO POP & MORE

After nearly two years of all smoke, no fire around President Trump's promise to curtail drug prices, there's finally some glimmer...

Pharma giant Merck just lowered the prices of some of its medications

PHARMA GIANT MERCK JUST LOWERED THE PRICES OF SOME OF ITS MEDICATIONS

AP Merck said Thursday that it would lower the price of some of its medications including its hepatitis C drug Zepatier by 60%. The...

 
 
 
Former Beyoncé Manager Merck Mercuriadis Raises $260 Million In IPO for Hipgnosis Songs

FORMER BEYONCÉ MANAGER MERCK MERCURIADIS RAISES $260 MILLION IN IPO FOR HIPGNOSIS SONGS

Hipgnosis Songs, a music IP investment company set up by former Beyoncé and Guns N' Roses manager Merck Mercuriadis, has raised £200...

Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On

BIO ROUNDUP: BIG BUCKS FOR CALICO, DATA DUMPS & THE IPO WAVE ROLLS ON

If you're running a privately held biotech, the time to go public is now. Clinical data already in hand or not, biotechs have charged...

 
 
 
AstraZeneca's PARP Drug Is First to Help New Ovarian Cancer Patients

ASTRAZENECA'S PARP DRUG IS FIRST TO HELP NEW OVARIAN CANCER PATIENTS

Over the past few years, a new class of drugs known as “PARP” inhibitors have begun to change how ovarian cancer is treated. Data released...

Emulate Adds $36M to Expand “Organ Chip” Drug Research Technology

EMULATE ADDS $36M TO EXPAND “ORGAN CHIP” DRUG RESEARCH TECHNOLOGY

Emulate, a Boston-based startup that has developed small laboratory chips intended to replace the animal tests used in pharmaceutical...

 
 
 
Understanding the Patient Voice: Unique Perspectives on Healthcare

UNDERSTANDING THE PATIENT VOICE: UNIQUE PERSPECTIVES ON HEALTHCARE

To end Day 2 of Education Tracks at the 2018 BIO International Convention , Julie Gerberding, Executive Vice President & Chief Patient...

 
 
 

ONCOSEC PRESENTS UPDATE ON PISCES/KEYNOTE-695 PHASE 2B REGISTRATION-DIRECTED CLINICAL TRIAL IN COMBINATION WITH MERCK'S KEYTRUDA® FOR METASTATIC MELANOMA AT THE ASCO 2018 ANNUAL MEETING

SAN DIEGO, June 4, 2018 /PRNewswire/ - OncoSec Medical Incorporated , a company developing intratumoral cancer immunotherapies, today...

 
 
 
 
 
 
Akili Grabs $55M, Seeking FDA Approval of First Video Game Therapy

AKILI GRABS $55M, SEEKING FDA APPROVAL OF FIRST VIDEO GAME THERAPY

Akili Interactive Labs has scooped up another pile of cash to help bring its first product to the market-an experimental mobile video...

 
 
 
Merck Immunotherapy Drug Shines In Lung Cancer Study

MERCK IMMUNOTHERAPY DRUG SHINES IN LUNG CANCER STUDY

Research finds that more than two-thirds of lung cancer patients who received Keytruda plus chemotherapy would be alive a year later,...

New immunotherapy drug becomes first ever to DOUBLE survival in lung cancer patients

NEW IMMUNOTHERAPY DRUG BECOMES FIRST EVER TO DOUBLE SURVIVAL IN LUNG CANCER PATIENTS

Merck's Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone...

 
 
 
 
 
 
Despite Pain Drug's Mid-Stage Miss, Adynxx Plans a Larger Phase 3 Test

DESPITE PAIN DRUG'S MID-STAGE MISS, ADYNXX PLANS A LARGER PHASE 3 TEST

An Adynxx pain drug has failed to meet the main goal of a mid-stage study, but the company instead points to results in a subset of...

IMMUNOGEN STOCK CLIMBS ON POSITIVE OVARIAN CANCER DATA

ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination...